Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 9;35(8):1426–1436. doi: 10.1111/jgh.14986

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Interferon‐stimulated gene 20 (ISG20) is involved in interferon (IFN)‐β‐mediated suppression of hepatitis B virus (HBV). (a) The mRNA and protein level of ISG20 induced by IFNs. To detect the mRNA level of ISG20, HepG2 cells were treated with the indicated IFNs (100 IU) for 3 or 6 h (left upper panel). N, negative control. The indicated IFNs (500 IU) were treated for 24 h (right panel). In a dose‐dependent manner, IFN‐β was treated for 24 h. Figure represented the representative data obtained from three independent experiments. (b) Effect of siISG20 (20 nM) on IFN‐β‐mediated suppression of HBV. , HBeAg; □, HBsAg. Values represent the mean ± SD calculated from at least three independent experiments. ^* P < 0.05, ^** P < 0.005. P values were determined using unpaired t‐test. (c) Expression level of ISG20 during natural course of chronic hepatitis B in patients. IA, immune activation; IC, inactive carrier; IT, immune tolerance. ^** P < 0.001, ^*** P < 0.0001. [Correction added on 22 February 2020, after first online publication: figure image and caption have been amended.]

Inline graphic — Interferon‐stimulated gene 20 (ISG20) is involved in interferon (IFN)‐β‐mediated suppression of hepatitis B virus (HBV). (a) The mRNA and protein level of ISG20 induced by IFNs. To detect the mRNA level of ISG20, HepG2 cells were treated with the indicated IFNs (100 IU) for 3 or 6 h (left upper panel). N, negative control. The indicated IFNs (500 IU) were treated for 24 h (right panel). In a dose‐dependent manner, IFN‐β was treated for 24 h. Figure represented the representative data obtained from three independent experiments. (b) Effect of siISG20 (20 nM) on IFN‐β‐mediated suppression of HBV. , HBeAg; □, HBsAg. Values represent the mean ± SD calculated from at least three independent experiments. ^* P < 0.05, ^** P < 0.005. P values were determined using unpaired t‐test. (c) Expression level of ISG20 during natural course of chronic hepatitis B in patients. IA, immune activation; IC, inactive carrier; IT, immune tolerance. ^** P < 0.001, ^*** P < 0.0001. [Correction added on 22 February 2020, after first online publication: figure image and caption have been amended.]